p.104 抽出テキスト

355. Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Lip GYH, et al. Application of the simple atrial fibrillation better care pathway for integrated care management in frail patients with atrial fibrillation: a nationwide cohort study. J Arrhythm 2020;36:668–677. https://doi. org/10.1002/joa3.12364 356. Romiti GF, Proietti M, Vitolo M, Bonini N, Fawzy AM, Ding WY, et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med 2022;20:326. https://doi.org/10.1186/ s12916-022-02526-7 357. Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Uhm JS, et al. The effect of integrated care management on dementia in atrial fibrillation. J Clin Med 2020;9:1696. https://doi.org/ 10.3390/jcm9061696 358. Kotalczyk A, Guo Y, Stefil M, Wang Y, Lip GYH, Chi ORI. Effects of the atrial fibrillation better care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy: a report from the ChiOTEAF registry. J Am Heart Assoc 2022;11:e024319. https://doi.org/10.1161/JAHA.121.024319 359. Esteve-Pastor MA, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Cequier A, et al. Impact of integrated care management on clinical outcomes in atrial fibrillation patients: a report from the FANTASIIA registry. Front Cardiovasc Med 2022;9:856222. https://doi.org/10.3389/fcvm.2022.856222 360. Guo Y, Imberti JF, Kotalczyk A, Wang Y, Lip GYH, Chi ORI. 4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients. Eur J Clin Invest 2022;52:e13751. https://doi.org/10.1111/eci.13751 361. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol 2020;75: 1523–1534. https://doi.org/10.1016/j.jacc.2020.01.052 362. Guo Y, Guo J, Shi X, Yao Y, Sun Y, Xia Y, et al. Mobile health technology-supported atrial fibrillation screening and integrated care: a report from the mAFA-II trial longterm extension cohort. Eur J Intern Med 2020;82:105–111. https://doi.org/10.1016/j. ejim.2020.09.024 363. Koniaris LS, Goldhaber SZ. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol 1998;31:745–748. https://doi.org/10.1016/S0735-1097(98)00003-5 364. Eapen ZJ, Mi X, Fonarow GC, Setoguchi S, Piccini JP, Mills RM, et al. Anticoagulation and clinical outcomes in heart failure patients with atrial fibrillation: findings from the ADHERE registry. J Atr Fibrillation 2013;6:953. 365. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014;100:465–472. https://doi.org/10.1136/heartjnl-2013-304276 366. Camm CF, Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev 2017;6:63–68. https://doi.org/10.15420/ aer.2017:4:2 367. Nasser MF, Gandhi S, Siegel RJ, Rader F. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review. Heart Rhythm 2021;18:297–302. https://doi.org/10.1016/j.hrthm.2020.09.018 368. van Rijsingen IAW, Bakker A, Azim D, Hermans-van Ast JF, van der Kooi AJ, van Tintelen JP, et al. Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. Int J Cardiol 2013;168: 472–477. https://doi.org/10.1016/j.ijcard.2012.09.118 369. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 2015;17:837–845. https://doi.org/10.1002/ejhf.316 370. Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2021;23: 895–905. https://doi.org/10.1002/ejhf.2198 371. Jung H, Yang P-S, Sung J-H, Jang E, Yu HT, Kim T-H, et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 2019;119:285–293. https://doi.org/10.1055/ s-0038-1676818 372. Jung H, Sung J-H, Yang P-S, Jang E, Yu HT, Kim T-H, et al. Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2018;72: 2409–2411. https://doi.org/10.1016/j.jacc.2018.07.098 373. Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail 2022;24: 1387–1396. https://doi.org/10.1002/ejhf.2566 374. Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Effectiveness and safety of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest 2019;155:354–363. https://doi.org/10.1016/j.chest.2018.11.009 375. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554–1568. https://doi. org/10.1093/eurheartj/ehab072 376. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 955–962. https://doi.org/10.1016/S0140-6736(13)62343-0 377. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015;17: 1192–1200. https://doi.org/10.1002/ejhf.343 378. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. J Am Coll Cardiol 2016;67:3020–3021. https://doi.org/10.1016/j.jacc.2016.04.026 379. Lee HJ, Kim HK, Jung JH, Han KD, Lee H, Park JB, et al. Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Stroke 2019;50:2582–2586. https://doi.org/10.1161/STROKEAHA.119.026048 380. Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with nonvalvular atrial fibrillation. Heart Vessels 2022;37:1224–1231. https://doi.org/10.1007/ s00380-022-02021-2 381. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363–1373. https://doi.org/10.1056/NEJMoa1001337 382. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935–942. https:// doi.org/10.1093/europace/eul106 383. Sartipy U, Savarese G, Dahlstrom U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:471–479. https://doi.org/10.1002/ejhf.1389 384. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines – Heart Failure Program). Am J Cardiol 2020; 125:894–900. https://doi.org/10.1016/j.amjcard.2019.12.025 385. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet 2016;388:818–828. https://doi.org/10.1016/S0140-6736(16)31258-2 386. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol 2017;69:2885–2896. https://doi.org/10.1016/j.jacc.2017.04.001 387. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020;324:2497–2508. https://doi.org/10. 1001/jama.2020.23138 388. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555 389. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42: 4731–4739. https://doi.org/10.1093/eurheartj/ehab569 390. Huang W, Wang S, Su L, Fu G, Su Y, Chen K, et al. His-bundle pacing vs biventricular pacing following atrioventricular nodal ablation in patients with atrial fibrillation and reduced ejection fraction: a multicenter, randomized, crossover study–The ALTERNATIVE-AF trial. Heart Rhythm 2022;19:1948–1955. https://doi.org/10.1016/ j.hrthm.2022.07.009 391. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart 2017;103: 672–678. https://doi.org/10.1136/heartjnl-2016-309672 392. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305–315. https://doi.org/10.1056/NEJMoa2029980 393. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–324. https:// doi.org/10.1056/NEJMoa2029554 394. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011;13:329–345. https://doi.org/10.1093/ europace/euq450 395. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358: 2678–2687. https://doi.org/10.1056/NEJMoa0800456 396. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–2276. https://doi. org/10.1056/NEJMoa1109867 397. Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 2016;102:1533–1543. https://doi.org/10.1136/heartjnl-2016- 309406 398. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026